Quote:

---

would 10% of trial participants survival give a qualifying p-value?

---

Around 84% of sepsis patients recover with current treatment. Severe cases of sepsis recovery is around 75%. With septic shock recovery goes down to 50%. Most likely any trial would use severe sepsis as a basis. Going for septic shock there may not be enough time for leronlimab to take effect in many cases. There would also be more potential patients in severe.

The trial would be leronlimab + SOC vs. SOC. with a 500 patient trial to be on the safe side you'd probably want to see 15% recovery over current SOC or 86.25% recovery in the leronlimab arm

Quote:

---

the financial home run is easy too...10% of 270,000 deaths per year = 27,000 x approx $2000 per dose = $54,000,000 / year not too bad

---

Current pricing is $1153 per 700mg dose. If leronlimab becomes the new standard of care I think you could see at least 25% of the 990,000 patients with severe or greater sepsis treated with it. Why doctors would use it in such frequency is not only saving lives but would mitigate serious complications. Let's say an average of 3 doses. 247,500 patients X $3459 = $856 million.